Overview Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease Status: Completed Trial end date: 2021-09-02 Target enrollment: Participant gender: Summary This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. Phase: Phase 3 Details Lead Sponsor: Idorsia Pharmaceuticals Ltd.